EUCTR2006-005299-42-ES进行中（未招募）不适用
Estudio multicéntrico abierto randomizado que compara ciclosporina e infliximab para el tratamiento de la colitis ulcerosa grave corticorrefractaria.A randomized multicenter open label study comparing cyclosporine with infliximab in steroid-refractory severe attacks of ulcerative colitis - CYSIF
GETECCU (Grupo Español para el estudio de la enfermedad de Crohn y la colitis ulcerosa)0 个研究点目标入组 100 人开始时间: 2008年3月3日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •?Age > 18 years.
- •?Diagnosis of UC according to Lennard-Jones criteria (Appendix 1).
- •?Endoscopically demonstrated colorectal lesions localized above the anal margin and extending at least up to 15cm proximally.
- •?Severe acute flare of UC with a Lichtiger Index score > 10 (Appendix 2).
- •?Refractoriness to high dose intravenous steroid therapy (= 0.8 mg/kg/d of methylprednisolone or equivalent) given for at least 5 days.
- •?Adequate contraception for male or female subjects of childbearing potential, which will be continued throughout the study and at least 3 months after study termination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •?Pregnant or breast-feeding woman.
- •?Previous treatment with cyclosporine or infliximab.
- •?Azathioprine or 6-mercaptopurine treatment initiated more than 4 weeks before inclusion.
- •?Indication for immediate surgery.
- •?History of colorectal dysplasia.
- •?Diagnosis of Crohn's disease.
- •?Positive stool tests for amoebiasis and/or positive bacteriological culture for Salmonella, Shigella, Yersinia and Campylobacter and/or presence of Clostridium difficile B toxin in the stools.
- •?Renal failure (creatininemia > upper limit of normal laboratory value).
- •?Uncontrolled high blood pressure.
- •?HIV, HBV viral infection (except the presence of positive anti-HBs antibodies) with serology not older than 3 months.
- •?Uncontrolled bacterial or active viral infection.
- •?Past medical history of malignant condition in the last 5 years (including leukaemia, lymphoma and myelodysplasia) except for baso-cellular cutaneous cancers.
- •?Past medical history of myocardial infarction or heart failure.
- •?Intradermal reaction to Tuberculin (Tubertest® 5 units) > 5mm.
- •?Active tuberculosis
- •?Untreated latent tuberculosis (see national recommendations. Appendix 3).
- •?Abnormal blood count with polynuclear neutrophils < 1,500 G/L or white cells < 3,000, or platelets < 100,000 G/L.
- •?Unexplained rise higher than 3 times the normal level for transaminases, alkaline phosphatases and/or higher than twice the normal level for bilirubin.
- •?Non-compliant subjects.
- •?Participation in another therapeutic study.
研究者
相似试验
进行中（未招募）
不适用
Estudio multicéntrico, abierto, randomizado, de doce meses de duración, sobre la seguridad, tolerabilidad y eficacia de Certican®, administrado junto a un antagonista del receptor IL-2, corticoesteroides y dos niveles de exposición diferentes de tacrolimus, en pacientes con trasplante renal de novoTransplante renal de novode novo kidney transplantationEUCTR2005-001714-41-ESovartis Farmacéutica, S.A.230
进行中（未招募）
1 期
Estudio multicéntrico, abierto, randomizado, controlado, dos grupos, para evaluar el cumplimiento de la toma diaria en mujeres usuarias de contracepción oral con SHT00186D/BAY 86-5300 (0.02 mg de etinilestradiol como clatrato de betadex, y 3 mg de Drospirenona) en un régimen extendido y flexible, con el apoyo de un dispensador (CADDY) con función de recordatorio, durante 12 meses. (A multicenter, open-label, randomized, controlled, two-arm study to assess compliance with daily tablet intake of women on treatment with the oral contraceptive SH T00186D/BAY 86-5300 (0.02 mg ethinyl estradiol as betadex clathrate and 3 mg drospirenone) in a flexible extended regimen supported by a dispenser (CADDY) with a reminder function over 12 months) - EU-Compliance by buzzer study of YAZ Flex in the CADDYEUCTR2010-019902-17-ESBayer HealthCare AG
进行中（未招募）
1 期
Estudio multicentrico, randomizado, abierto, para evaluar el inhibidor de la poli (ADP-ribosa) polimerasa 1 (PARP-1), BSI-201, administrado una o dos veces por semana, en combinación con gemcitabina/carboplatino en pacientes con cáncer de mama avanzado o metastásico triple negativo (mTNBC)__________________________________________________Multicenter, randomized, open label study evaluating a poly(ADP-ribose) polymerase-1(PARP-1) inhibitor, SAR240550 (BSI-201), administered twice weekly or weekly, in combination with gemcitabine/carboplatin, in patients with metastatic Triple Negative Breast Cancer (mTNBC)EUCTR2009-016091-80-ESsanofi-aventis recherche & développement80
进行中（未招募）
不适用
Estudio abierto, randomizado, multicéntrico para comparar la eficacia y la seguridad de la prednisona y granulocitoféresis con Adacolumn® versus la prednisona sola en el tratamiento de pacientes con colitis ulcerosa activa corticodependiente leve a moderada.Colitis ulcerosa corticodependiente leve o moderadaMedDRA version: 9.1Level: LLTClassification code 10045365Term: Ulcerative colitisEUCTR2007-003815-30-ESGETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa)
进行中（未招募）
1 期
Etude multicentrique randomisée ouverte comparant la réduction virale et la tolérancede l’association IFN alpha-2b XL + ribavirine versus IFN peg alpha-2b + ribavirine chez despatients atteints d’hépatite chronique C de génotype 1 - COAT-IFEvaluation de l’activité antivirale d’injections hebdomadaires d’un nouvel interféron a-2b à libération prolongée formulé avec Medusa® (IFNa-2bXL) chez des patients atteints d’hépatite chronique virale C génotype 1.MedDRA version: 12.0Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2009-015121-37-FRANRS